Show simple item record

dc.contributor.authorWeiss, SL
dc.contributor.authorBalamuth, F
dc.contributor.authorLong, E
dc.contributor.authorThompson, GC
dc.contributor.authorHayes, KL
dc.contributor.authorKatcoff, H
dc.contributor.authorCook, M
dc.contributor.authorTsemberis, E
dc.contributor.authorHickey, CP
dc.contributor.authorWilliams, A
dc.contributor.authorWilliamson-Urquhart, S
dc.contributor.authorBorland, ML
dc.contributor.authorDalziel, SR
dc.contributor.authorGelbart, B
dc.contributor.authorFreedman, SB
dc.contributor.authoret al.
dc.date.accessioned2021-11-24T01:00:29Z
dc.date.available2021-11-24T01:00:29Z
dc.date.issued2021
dc.identifier.issn1745-6215
dc.identifier.doi10.1186/s13063-021-05717-4
dc.identifier.urihttp://hdl.handle.net/10072/410326
dc.description.abstractBackground/aims: Despite evidence that preferential use of balanced/buffered fluids may improve outcomes compared with chloride-rich 0.9% saline, saline remains the most commonly used fluid for children with septic shock. We aim to determine if resuscitation with balanced/buffered fluids as part of usual care will improve outcomes, in part through reduced kidney injury and without an increase in adverse effects, compared to 0.9% saline for children with septic shock. Methods: The Pragmatic Pediatric Trial of Balanced versus Normal Saline Fluid in Sepsis (PRoMPT BOLUS) study is an international, open-label pragmatic interventional trial being conducted at > 40 sites in the USA, Canada, and Australia/New Zealand starting on August 25, 2020, and continuing for 5 years. Children > 6 months to < 18 years treated for suspected septic shock with abnormal perfusion in an emergency department will be randomized to receive either balanced/buffered crystalloids (intervention) or 0.9% saline (control) for initial resuscitation and maintenance fluids for up to 48 h. Eligible patients are enrolled and randomized using serially numbered, opaque envelopes concurrent with clinical care. Given the life-threatening nature of septic shock and narrow therapeutic window to start fluid resuscitation, patients may be enrolled under “exception from informed consent” in the USA or “deferred consent” in Canada and Australia/New Zealand. Other than fluid type, all decisions about timing, volume, and rate of fluid administration remain at the discretion of the treating clinicians. For pragmatic reasons, clinicians will not be blinded to study fluid type. Anticipated enrollment is 8800 patients. The primary outcome will be major adverse kidney events within 30 days (MAKE30), a composite of death, renal replacement therapy, and persistent kidney dysfunction. Additional effectiveness, safety, and biologic outcomes will also be analyzed. Discussion: PRoMPT BOLUS will provide high-quality evidence for the comparative effectiveness of buffered/balanced crystalloids versus 0.9% saline for the initial fluid management of children with suspected septic shock in emergency settings. Trial registration: PRoMPT BOLUS was first registered at ClinicalTrials.gov (NCT04102371) on September 25, 2019. Enrollment started on August 25, 2020.
dc.description.peerreviewedYes
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofissue1
dc.relation.ispartofjournalTrials
dc.relation.ispartofvolume22
dc.subject.fieldofresearchCardiology (incl. cardiovascular diseases)
dc.subject.fieldofresearchcode320101
dc.subject.keywordsSepsis
dc.subject.keywordsSeptic shock
dc.subject.keywordsPediatric
dc.subject.keywordsIntravenous fluid
dc.subject.keywordsCrystalloid
dc.subject.keywordsSaline
dc.subject.keywordsRenal failure
dc.subject.keywordsPragmatic trial
dc.titlePRagMatic Pediatric Trial of Balanced vs nOrmaL Saline FlUid in Sepsis: study protocol for the PRoMPT BOLUS randomized interventional trial
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationWeiss, SL; Balamuth, F; Long, E; Thompson, GC; Hayes, KL; Katcoff, H; Cook, M; Tsemberis, E; Hickey, CP; Williams, A; Williamson-Urquhart, S; Borland, ML; Dalziel, SR; Gelbart, B; Freedman, SB; Babl, FE; Huang, J; Kuppermann, N; Long, E; Williams, A; Babl, F; Borland, M; O’Brien, S; Craig, S; Ramaga, E; Kochar, A; Nivea, G; Jani, S; Thosar, D; Rao, A; Phillips, N; George, S; Lithgow, A; Mitchell, C; Thompson, G; Freedman, S; Gilad, E; Cooke, S; Judge, P; Murthy, S; Kissoon, N; Alqurashi, W; Alnaji, F; Sangha, G; Mater, A; Brashaw, M; Curtis, S; Joffe, A; Shayan, Y; Tucci, M; Gripp, K; Berthelot, S; Weiss, M; Davis, A; Guifoyle, E; Moretti, M; Kam, A; Parker, M; Rochwerg, B; Emsley, J; Verma, N; Sehgal, A; Dalziel, S; Bonisch, M; Tan, E; Neutze, J; Balamuth, F; Weiss, S; Huang, J; Cook, M; Hayes, K; Hickey, C; Eisenberg, M; Lewander, D; Morris, C; Hurley, D; Baumer-Mouradian, S; Ambroggio, L; Grice, K; Festekjian, A; Hickey, B; Sada, R; Dodson, J; Badawy, M; Lebel, C; Elliott, M; Koutralis, I; Hom, K; Eckerle, M; Singleton, M; Rogers, A; Cervantes, V; Duffy, S; Bahamon, I; Alpern, L; Sirizi, A; Ahmad, AH, PRagMatic Pediatric Trial of Balanced vs nOrmaL Saline FlUid in Sepsis: study protocol for the PRoMPT BOLUS randomized interventional trial, Trials, 2021, 22 (1)
dcterms.licensehttp://creativecommons.org/licenses/by/4.0/
dc.date.updated2021-11-24T00:42:32Z
dc.description.versionAccepted Manuscript (AM)
gro.rights.copyright© 2021 by the authors. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
gro.hasfulltextFull Text
gro.griffith.authorGeorge, Shane A.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record